Literature DB >> 8471430

The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment.

B D Kavanagh1, B E Coffey, D Needham, R M Hochmuth, M W Dewhirst.   

Abstract

Flunarizine is a class IV calcium channel blocker which increases oxygen delivery to hypoxic regions in solid tumours, exerting a radiosensitising effect in vivo in animal tumour models. Precisely how the drug improves oxygenation is not well understood. We hypothesised that metabolic conditions present within solid tumours reduce red blood cell (RBC) deformability and that flunarizine exerts its in vivo effect by preventing this loss of RBC deformability. A microrheometer was used to compare the viscosity of rat and human RBC suspensions in conditions of hypoxia (pO2 < 10 mmHg), acidic environment (pH 6.8), and elevated lactate concentration (lactate 5 mMol l-1), without or with flunarizine at concentrations of 5, 10, and 50 mg l-1. The effects of flunarizine on RBC density and morphology were also recorded. Hypoxia, low pH, and lactate exposure together increased both human and rat RBC suspension viscosity. Flunarizine at concentrations of 5 and 10 mg l-1 prevented the increases in viscosity. The drug caused dose-dependent shifts toward lower cell density while inducing a characteristic cupped shape (stomatcytic morphology), suggesting a mechanism involving calmodulin inhibition. The results support the hypothesis that flunarizine improves tumour blood flow and oxygenation by enhancing flow properties of RBC's in solid tumours.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471430      PMCID: PMC1968366          DOI: 10.1038/bjc.1993.134

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  39 in total

1.  THE INTERSTITIAL FLUID OF SOLID TUMORS.

Authors:  P M GULLINO; S H CLARK; F H GRANTHAM
Journal:  Cancer Res       Date:  1964-06       Impact factor: 12.701

2.  Spin label study of erythrocyte deformability. Ca2+-induced loss of deformability and the effects of stomatocytogenic reagents on the deformability loss in human erythrocytes in shear flow.

Authors:  S Noji; S Taniguchi; H Kon
Journal:  Biophys J       Date:  1987-08       Impact factor: 4.033

3.  Modification of tumour response by calcium antagonists in the SCVII/St tumour implanted at two different sites.

Authors:  P J Wood; D G Hirst
Journal:  Int J Radiat Biol       Date:  1989-09       Impact factor: 2.694

4.  The influence of red cell mechanical properties on flow through single capillary-sized pores.

Authors:  R S Frank; R M Hochmuth
Journal:  J Biomech Eng       Date:  1988-05       Impact factor: 2.097

5.  Prevention of calcium-induced membrane structural alterations in erythrocyte membranes by flunarizine.

Authors:  P G Thomas; A G Zimmermann; A J Verkleij
Journal:  Biochim Biophys Acta       Date:  1988-12-22

6.  Decreased red cell filterability in patients with acute myocardial infarction.

Authors:  L Waldenlind; B L Edlund; J Hulting; J Karnell; F Lund; G Rosenhamer
Journal:  Acta Med Scand       Date:  1988

Review 7.  Determinants of tumor blood flow: a review.

Authors:  R K Jain
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

8.  Effect of hypoxia on erythrocyte deformability in different species.

Authors:  T S Hakim; A S Macek
Journal:  Biorheology       Date:  1988       Impact factor: 1.875

9.  Clinical assay of the human erythrocyte lactate transporter. II. Analysis and display of normal human data.

Authors:  W N Fishbein; J I Davis; J W Foellmer; M R Casey
Journal:  Biochem Med Metab Biol       Date:  1988-06

10.  Cinnarizine and flunarizine as radiation sensitisers in two murine tumours.

Authors:  P J Wood; D G Hirst
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

View more
  12 in total

Review 1.  Transport of drugs from blood vessels to tumour tissue.

Authors:  Mark W Dewhirst; Timothy W Secomb
Journal:  Nat Rev Cancer       Date:  2017-11-10       Impact factor: 60.716

2.  Arteriolar oxygenation in tumour and subcutaneous arterioles: effects of inspired air oxygen content.

Authors:  M W Dewhirst; E T Ong; G L Rosner; S W Rehmus; S Shan; R D Braun; D M Brizel; T W Secomb
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 3.  Changes in the Blood Viscosity in Patients With SARS-CoV-2 Infection.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Sadiq M Al-Hamash; Simona Cavalu; Maisra M El-Bouseary; Fatma I Sonbol; Gaber El-Saber Batiha
Journal:  Front Med (Lausanne)       Date:  2022-06-17

Review 4.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

Review 5.  Novel imaging provides new insights into mechanisms of oxygen transport in tumors.

Authors:  Matthew E Hardee; Mark W Dewhirst; Nikita Agarwal; Brian S Sorg
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 6.  Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress.

Authors:  Mark W Dewhirst
Journal:  Radiat Res       Date:  2009-12       Impact factor: 2.841

Review 7.  Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response.

Authors:  Mark W Dewhirst; Yiting Cao; Benjamin Moeller
Journal:  Nat Rev Cancer       Date:  2008-06       Impact factor: 60.716

8.  Decomposition of spontaneous fluctuations in tumour oxygenation using BOLD MRI and independent component analysis.

Authors:  Miguel R Gonçalves; S Peter Johnson; Rajiv Ramasawmy; R Barbara Pedley; Mark F Lythgoe; Simon Walker-Samuel
Journal:  Br J Cancer       Date:  2015-10-20       Impact factor: 7.640

Review 9.  Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs.

Authors:  Tomas Koltai
Journal:  F1000Res       Date:  2015-07-22

10.  Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.

Authors:  S M Castellino; H S Friedman; G B Elion; E T Ong; S L Marcelli; R Page; D D Bigner; M W Dewhirst
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.